‹ All questions

ABT vs Medtronic: which stock is doing better?

ABT and Medtronic are business rivals. Where they compete: cardiac/electrophysiology, neuromodulation, structural heart, vascular, core Medical Devices overlap. Here is how the two stocks, and the businesses behind them, compare over the past year.

Updated Oct 9, 2026

35
MDT P3

MDT ahead

On Stox’s P3 score, which combines market beat, staying power and business growth, Medtronic rates 35 and ABT 29. Over the past year ABT is −26% and Medtronic −10%, against +16% for the S&P 500. Both are the Falling Knife type.

ABT P3 29MDT P3 35Both in Health care

The past year

ABT against MDT, each set to $100 a year ago. Select a measure in the table below to chart it for both.

ABT against MDT, past year
$100 a year ago. ABT −26%, MDT −10%.
6080100NovDecJanFebMarAprMayJunJulAugSepOct
ABTMDT

ABT and MDT side by side

Ahead marks the stronger reading on each line; for the typical day and the deepest fall it marks the steadier stock. Select a row with a chart to see both over the year.

MeasureABTMDTAhead
Past 3 months
Share price change
+8%+6%ABT
Past month
Share price change
−4%−3%Level
Revenue growth
Past four quarters against the year before
+7%+7%Level
Operating margin
Operating profit as a share of revenue, past four quarters
18%18%Level
Deepest fall
From a high, past year
−38%−30%MDT, held up
Market value
What the market values the company at
$172.3B$113.3B
Type
Its Stox Atlas type
Falling KnifeFalling Knife
Group
Stocks it moves with
Health careHealth careSame group

How to read this page

How it’s measured. Scores from Stox rank each stock against about 1,200 large US stocks and funds, where 100 is best; P3 combines market beat, staying power and business growth. Returns are share-price changes. The typical day is the average true range over 14 days as a share of the price, averaged over the past year.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and curated rivals from Stox.

A higher score describes a stronger past year, not what comes next.

Rivals are chosen by the markets the two businesses compete in, not by sector labels.

For financial statements, valuation and news, see ABT and MDT on Stox.

This page is information, not investment advice. About our data and methods ›

More head-to-heads

See all questions ›